KRAS Inhibitor Patents

KRAS inhibitor patents cover G12C-covalent-inhibitor innovations; G12D and other-mutant innovations; pan-RAS and tri-complex innovations; and upstream-pathway and combination innovations — with IP held by the G12C pioneers and next-generation RAS-targeting companies (in a field that finally drugged the long-'undruggable' KRAS oncogene). MAJOR KRAS-INHIBITOR PATENT HOLDERS: AMGEN: Lumakras (sotorasib / AMG 510), the FIRST approved KRAS inhibitor — a covalent inhibitor of KRAS G12C (the glycine-to-cysteine mutation common in lung/colorectal cancer) — plus the composition-of-matter and follow-on estate. MIRATI THERAPEUTICS (Bristol Myers Squibb): Krazati (adagrasib), a second KRAS G12C covalent inhibitor, plus MRTX1133 (a KRAS G12D non-covalent inhibitor — a harder, larger-population target). REVOLUTION MEDICINES: a 'tri-complex' platform creating inhibitors that recruit cyclophilin A to form a complex that binds RAS — RMC-6236 (a RAS(ON) multi-selective inhibitor hitting multiple RAS mutants in the active GTP-bound state), RMC-6291 (G12C), and RMC-9805 (G12D) — a fundamentally different, broad mechanism. OTHERS: Boehringer Ingelheim (G12C and pan-KRAS), Roche/Genentech (divarasib, a more-selective G12C), Eli Lilly, Jacobio, InventisBio, and SOS1/SHP2 upstream-inhibitor holders. Covalent G12C inhibitors, G12D inhibitors, and pan-RAS/tri-complex mechanisms are the core KRAS patent domains — and the inhibitor molecule (composition-of-matter) is the durable asset.

Covalent-warhead and binding-pocket innovations; G12C-specific composition innovations; G12D and other-mutant innovations; and selectivity and pharmacology innovations represent core KRAS-inhibitor patent domains — and the specific inhibitor molecule that exploits a mutant-specific pocket is the heart of KRAS IP. G12C-COVALENT PATENTS: small molecules that covalently bind the mutant cysteine-12 of KRAS G12C (via an acrylamide/electrophilic 'warhead') and lock the protein in its inactive GDP-bound 'off' state, binding the cryptic switch-II pocket discovered by Shokat — including the specific molecule as composition-of-matter (sotorasib, adagrasib, divarasib are distinct patented chemotypes), warhead chemistry, and the switch-II-pocket-binding scaffold. G12D PATENTS: KRAS G12D is harder (no reactive cysteine for a covalent warhead — it has an aspartate), so NON-COVALENT inhibitors (Mirati MRTX1133) or covalent approaches targeting other residues, plus the larger G12D patient population make this a high-value, competitive target. OTHER-MUTANT PATENTS: G12V, G13D, Q61, and tumor-specific mutants. SELECTIVITY / PHARMACOLOGY PATENTS: mutant-selectivity over wild-type KRAS (sparing normal RAS — a safety advantage), oral bioavailability, brain penetration (for CNS metastases), and pharmacokinetics. The specific inhibitor molecule (composition-of-matter), the warhead/pocket chemistry, and mutant-selectivity are the highest-value KRAS-inhibitor IP — and as with any drug, composition-of-matter on the molecule gives the durable ~20-year protection.

Pan-RAS and multi-selective innovations; tri-complex-mechanism innovations; upstream-pathway (SOS1/SHP2) innovations; and combination and resistance innovations represent additional KRAS-inhibitor patent domains — and broadening beyond single mutants plus overcoming resistance are the frontiers. PAN-RAS / TRI-COMPLEX PATENTS: Revolution Medicines' tri-complex approach — a small molecule that binds cyclophilin A, and the resulting binary complex then binds RAS, creating a novel composite surface — enabling inhibition of RAS in its ACTIVE (GTP-bound, 'RAS-ON') state and across MULTIPLE mutants (a 'RAS multi-selective' or pan-RAS inhibitor, RMC-6236) — a fundamentally different, broadly-protectable mechanism (the tri-complex chemistry and the RAS-ON binding are key claims); other pan-KRAS and RAS-ON approaches. UPSTREAM-PATHWAY PATENTS: inhibitors of SOS1 (the guanine-exchange factor that activates RAS) and SHP2 (a phosphatase upstream), used alone or in combination to suppress RAS signaling and resistance. COMBINATION PATENTS: combinations to overcome the rapid adaptive RESISTANCE that limits single-agent G12C inhibitors (G12C + SHP2/SOS1/EGFR/MEK, or G12C + immunotherapy), and resistance-mutation coverage. RESISTANCE / NEXT-GEN PATENTS: covering acquired resistance mutations and next-generation/RAS-ON inhibitors. The tri-complex/pan-RAS mechanism (broad, novel) and rational combinations to defeat resistance are the highest-value next-generation KRAS IP — because single-mutant G12C inhibitors face resistance and limited populations.

KRAS inhibitor startup IP strategy must navigate Amgen sotorasib and Mirati adagrasib G12C composition-of-matter and switch-II-pocket patents, Revolution Medicines tri-complex/RAS-ON patents, the foundational Shokat switch-II-pocket discovery (academic, UCSF — often licensable and underlying the field), the intense competition and rapid resistance, and a §101-light landscape (these are concrete molecules, not abstract ideas); understand that a specific KRAS inhibitor is composition-of-matter (durable), that G12C is crowded (Amgen/Mirati/Roche), and that the open, high-value frontiers are G12D, pan-RAS/RAS-ON mechanisms, resistance-overcoming combinations, and other mutants; identify whitespace in G12D, pan-RAS, novel mechanisms, combinations, and CNS-penetrant inhibitors. KRAS-INHIBITOR STARTUP IP STRATEGY: THE INHIBITOR MOLECULE IS COMPOSITION-OF-MATTER — THE DURABLE IP: patent the specific KRAS inhibitor (a new chemical entity, ~20-year protection) plus its warhead/pocket chemistry and mutant-selectivity; G12D AND PAN-RAS ARE HIGHEST-VALUE WHITESPACE — G12C IS CROWDED: G12C is densely patented (Amgen/Mirati/Roche); the bigger, less-consolidated opportunities are KRAS G12D (larger population, harder non-covalent chemistry — Mirati leads but room exists), pan-RAS/RAS-ON mechanisms (Revolution's tri-complex is one approach), and other mutants; NOVEL MECHANISMS (TRI-COMPLEX, RAS-ON) ARE BROADLY PROTECTABLE: a fundamentally different binding mechanism (active-state RAS, composite surfaces) covers more mutants and is more defensible than another switch-II G12C chemotype; COMBINATIONS TO DEFEAT RESISTANCE ARE PATENTABLE AND CLINICALLY ESSENTIAL: single-agent G12C inhibitors face rapid adaptive resistance — rational combinations (with SHP2/SOS1/EGFR or immunotherapy) are valuable method-of-treatment IP; CNS-PENETRANT AND SELECTIVE INHIBITORS ARE DIFFERENTIATORS: brain penetration (for metastases) and wild-type-sparing selectivity are clinically and patentably valuable; CHECK THE SHOKAT/UCSF SWITCH-II FOUNDATIONAL IP: the cryptic-pocket discovery underlies covalent G12C inhibitors — FTO/licensing consideration; WHEN TO PATENT: NOVEL INHIBITOR WITH MEASURED ACTIVITY: file composition-of-matter once a molecule shows measured results (target binding/IC50 + mutant selectivity + cellular/in vivo efficacy + PK/brain penetration + resistance coverage) — measured potency, mutant selectivity, efficacy, and resistance/CNS coverage are the critical KRAS IP metrics; KEY FTO CHECKLIST: Amgen sotorasib AMG 510 + Mirati adagrasib G12C covalent switch-II-pocket composition-of-matter; Roche divarasib selective G12C; Mirati MRTX1133 G12D non-covalent; Revolution tri-complex cyclophilin RAS-ON pan-RAS RMC-6236; Boehringer pan-KRAS; SOS1/SHP2 upstream inhibitors; covalent acrylamide warhead; wild-type-sparing selectivity; CNS penetration; resistance-overcoming combinations; Shokat/UCSF switch-II-pocket foundational FTO; composition-of-matter inhibitor.